Nkarta, Inc. Stock Price, News & Analysis

Nkarta, Inc. (Nasdaq: NKTX) announced its participation in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 3:30 p.m. ET. The company focuses on developing engineered natural killer (NK) cell therapies for cancer treatment. A live webcast of the presentation will be available on the company’s website, with a replay accessible for four weeks. Nkarta aims to enhance tumor targeting through its proprietary technologies and efficient manufacturing processes, advancing its pipeline of allogeneic NK cell therapies.

Nkarta, Inc. announced its first-quarter 2021 financial results, reporting a net loss of $19.4 million, or $0.59 per share. The company has cash and equivalents of $299.7 million, projected to support operations through at least mid-2023. Key developments include FDA clearance for NKX019, a CAR NK cell therapy targeting CD19, with patient dosing expected to begin in the second half of 2021. Additionally, amendments to the NKX101 trial will streamline patient enrollment and treatment. Nkarta is collaborating with CRISPR Therapeutics to advance its cell therapy pipeline.

Nkarta, Inc. (Nasdaq: NKTX) announced that the FDA has cleared its Investigational New Drug application for NKX019, a new CAR NK cell therapy targeting CD19 in patients with relapsed or refractory B cell malignancies. This marks the company’s second IND clearance within ten months. NKX019 is designed to enhance NK cell proliferation and activity using a membrane-bound form of IL-15. The Phase 1 clinical trial for NKX019 is set to begin in the second half of 2021, reinforcing Nkarta’s commitment to developing innovative cancer therapies derived from healthy donors.

Nkarta, Inc. (Nasdaq: NKTX) reported its financial results for Q4 and FY 2020, highlighting a cash position of $315.3 million as of December 31, 2020. The company is advancing its CAR NK cell therapies, with interim clinical data for NKX101 expected by year-end 2021 and an IND application for NKX019 planned for Q1 2021. R&D expenses totaled $36.2 million for 2020, while the net loss reached $91.4 million, or $5.44 per share. Nkarta anticipates sufficient cash to sustain operations into at least mid-2023.

Nkarta, Inc. (Nasdaq: NKTX) has announced its participation in several upcoming investor conferences, highlighting its focus on advancing NK cell therapies for cancer treatment. The events include the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, featuring a fireside chat at 1:40 p.m. ET, and the Cowen 41st Annual Health Care Conference on March 3-4, 2021, with no presentation scheduled. Additionally, Nkarta will present at the Barclays Global Healthcare Conference on March 11, 2021, at 10:20 a.m. ET. Live webcasts of these presentations will be available on their website.

Nkarta, Inc. has announced the dosing of the first patient in its Phase 1 clinical trial of NKX101, targeting acute myeloid leukemia and myelodysplastic syndromes. The company ended Q3 2020 with $330.2 million in cash, sufficient to fund operations through at least mid-2023. Nkarta plans to file an IND application for NKX019 in Q1 2021, focusing on B-cell malignancies. The Q3 financials revealed a net loss of $13.7 million, or $0.44 per share, alongside R&D expenses of $9.8 million and G&A expenses of $3.9 million.

Nkarta (Nasdaq: NKTX) has initiated its first-in-human Phase 1 clinical trial of NKX101 for treating relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). This multi-center trial aims to evaluate safety and preliminary anti-tumor activity. NKX101 is engineered to enhance natural killer (NK) cell response by targeting NKG2D, improving cytotoxic activity significantly in preclinical models. The trial addresses a critical need for effective treatments in AML patients, who have limited options and poor outcomes.

Nkarta, Inc. (Nasdaq: NKTX) has provided a preclinical update on NKX019, an investigational allogeneic cancer immunotherapy focused on treating B cell malignancies. The findings, presented at the SITC 35th Annual Meeting, indicate that NKX019 showed strong anti-tumor activity against CD19-expressing cancer models, outperforming non-engineered NK cells and demonstrating advantages over CAR T cells. Notably, NKX019 displayed reduced cytokine release syndrome risk, suggesting a favorable safety profile. Nkarta plans to file an IND application for NKX019 in Q1 2021 and initiate a Phase 1 trial for advanced B cell malignancies.

Nkarta, a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer, has announced its participation in several upcoming investor conferences.

The events include:

• Cowen 2020 IO Next Summit on November 13, 2020, at 11:45 a.m. ET
• Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 2:00 p.m. ET
• Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 9:40 a.m. ET

Audio webcasts will be available on Nkarta's website, with replays archived for about four weeks.